Published in J Virol on August 01, 1998
Escape and compensation from early HLA-B57-mediated cytotoxic T-lymphocyte pressure on human immunodeficiency virus type 1 Gag alter capsid interactions with cyclophilin A. J Virol (2007) 3.93
Assembly properties of the human immunodeficiency virus type 1 CA protein. J Virol (2004) 3.09
Abrogation of postentry restriction of HIV-1-based lentiviral vector transduction in simian cells. Proc Natl Acad Sci U S A (2003) 2.71
Cyclophilin interactions with incoming human immunodeficiency virus type 1 capsids with opposing effects on infectivity in human cells. J Virol (2005) 2.54
Target cell cyclophilin A modulates human immunodeficiency virus type 1 infectivity. J Virol (2004) 2.51
Catalysis of cis/trans isomerization in native HIV-1 capsid by human cyclophilin A. Proc Natl Acad Sci U S A (2002) 2.19
Cyclophilin A and TRIM5alpha independently regulate human immunodeficiency virus type 1 infectivity in human cells. J Virol (2006) 1.77
Comparative requirements for the restriction of retrovirus infection by TRIM5alpha and TRIMCyp. Virology (2007) 1.75
CD147 facilitates HIV-1 infection by interacting with virus-associated cyclophilin A. Proc Natl Acad Sci U S A (2001) 1.69
Cyclophilin A renders human immunodeficiency virus type 1 sensitive to Old World monkey but not human TRIM5 alpha antiviral activity. J Virol (2006) 1.69
Influence of gag on human immunodeficiency virus type 1 species-specific tropism. J Virol (2004) 1.57
Plunder and stowaways: incorporation of cellular proteins by enveloped viruses. J Virol (2005) 1.56
Lv1 inhibition of human immunodeficiency virus type 1 is counteracted by factors that stimulate synthesis or nuclear translocation of viral cDNA. J Virol (2004) 1.56
Target cell type-dependent modulation of human immunodeficiency virus type 1 capsid disassembly by cyclophilin A. J Virol (2009) 1.53
The double-stranded RNA-binding protein Staufen is incorporated in human immunodeficiency virus type 1: evidence for a role in genomic RNA encapsidation. J Virol (2000) 1.50
Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent. Antimicrob Agents Chemother (2008) 1.46
The ability of multimerized cyclophilin A to restrict retrovirus infection. Virology (2007) 1.43
Role of Vif in stability of the human immunodeficiency virus type 1 core. J Virol (2000) 1.34
Inhibition of HIV-1 infection by TNPO3 depletion is determined by capsid and detectable after viral cDNA enters the nucleus. Retrovirology (2011) 1.32
Cyclophilin A-dependent restriction of human immunodeficiency virus type 1 capsid mutants for infection of nondividing cells. J Virol (2008) 1.30
A mutation in alpha helix 3 of CA renders human immunodeficiency virus type 1 cyclosporin A resistant and dependent: rescue by a second-site substitution in a distal region of CA. J Virol (2007) 1.28
Cyclophilin A levels dictate infection efficiency of human immunodeficiency virus type 1 capsid escape mutants A92E and G94D. J Virol (2008) 1.27
Characterization of the behavior of functional viral genomes during the early steps of human immunodeficiency virus type 1 infection. J Virol (2009) 1.20
The immunosuppressant rapamycin represses human immunodeficiency virus type 1 replication. Antimicrob Agents Chemother (2002) 1.16
Analysis of human cell heterokaryons demonstrates that target cell restriction of cyclosporine-resistant human immunodeficiency virus type 1 mutants is genetically dominant. J Virol (2007) 1.13
HIV-1 uncoating: connection to nuclear entry and regulation by host proteins. Virology (2014) 1.12
Differential expression of HIV-1 interfering factors in monocyte-derived macrophages stimulated with polarizing cytokines or interferons. Sci Rep (2012) 1.12
HIV-1 capsid: the multifaceted key player in HIV-1 infection. Nat Rev Microbiol (2015) 1.11
Role of human immunodeficiency virus type 1 integrase in uncoating of the viral core. J Virol (2010) 1.07
Cyclophilin A promotes HIV-1 reverse transcription but its effect on transduction correlates best with its effect on nuclear entry of viral cDNA. Retrovirology (2014) 0.98
Strain-specific differences in the impact of human TRIM5alpha, different TRIM5alpha alleles, and the inhibition of capsid-cyclophilin A interactions on the infectivity of HIV-1. J Virol (2010) 0.95
Inhibition of HIV-1 multiplication by antisense U7 snRNAs and siRNAs targeting cyclophilin A. Nucleic Acids Res (2004) 0.95
Modulation of HIV-1 infectivity and cyclophilin A-dependence by Gag sequence and target cell type. Retrovirology (2009) 0.94
Gyrase B inhibitor impairs HIV-1 replication by targeting Hsp90 and the capsid protein. J Biol Chem (2010) 0.94
Cyclophilin A restricts influenza A virus replication through degradation of the M1 protein. PLoS One (2012) 0.92
Cyclophilin A-independent replication of a human immunodeficiency virus type 1 isolate carrying a small portion of the simian immunodeficiency virus SIV(MAC) gag capsid region. J Virol (2001) 0.92
Structural consequences of cyclophilin A binding on maturational refolding in human immunodeficiency virus type 1 capsid protein. J Virol (2001) 0.89
Heat shock protein-based therapeutic strategies against human immunodeficiency virus type 1 infection. Infect Dis Obstet Gynecol (1999) 0.84
Profiling of cellular proteins in porcine reproductive and respiratory syndrome virus virions by proteomics analysis. Virol J (2010) 0.81
Correlation of naturally occurring HIV-1 resistance to DEB025 with capsid amino acid polymorphisms. Viruses (2013) 0.81
Nuclear Envelope Protein SUN2 Promotes Cyclophilin-A-Dependent Steps of HIV Replication. Cell Rep (2016) 0.80
Delaying reverse transcription does not increase sensitivity of HIV-1 to human TRIM5α. PLoS One (2013) 0.76
Gene expression analysis of a panel of cell lines that differentially restrict HIV-1 CA mutants infection in a cyclophilin a-dependent manner. PLoS One (2014) 0.75
Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol (1986) 37.70
Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science (1984) 33.32
HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell (1990) 17.60
Cyclophilin and peptidyl-prolyl cis-trans isomerase are probably identical proteins. Nature (1989) 8.48
Cyclophilin: a specific cytosolic binding protein for cyclosporin A. Science (1984) 8.01
Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A and B. Cell (1993) 7.34
Specific incorporation of cyclophilin A into HIV-1 virions. Nature (1994) 7.13
Functional association of cyclophilin A with HIV-1 virions. Nature (1994) 6.82
Crystal structure of human cyclophilin A bound to the amino-terminal domain of HIV-1 capsid. Cell (1996) 6.74
Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells. J Virol (1993) 6.11
Peptidyl-prolyl cis-trans isomerase is the cyclosporin A-binding protein cyclophilin. Nature (1989) 5.86
Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes. J Virol (1992) 5.85
The role of T3 surface molecules in the activation of human T cells: a two-stimulus requirement for IL 2 production reflects events occurring at a pre-translational level. J Immunol (1984) 5.80
Structure of the amino-terminal core domain of the HIV-1 capsid protein. Science (1996) 5.44
Cyclophilin A is required for an early step in the life cycle of human immunodeficiency virus type 1 before the initiation of reverse transcription. J Virol (1996) 4.15
Molecular recognition in the HIV-1 capsid/cyclophilin A complex. J Mol Biol (1997) 3.50
Efficiency of viral DNA synthesis during infection of permissive and nonpermissive cells with vif-negative human immunodeficiency virus type 1. J Virol (1993) 3.12
The T cell activation factor NF-ATc positively regulates HIV-1 replication and gene expression in T cells. Immunity (1997) 2.66
Cyclosporine A-resistant human immunodeficiency virus type 1 mutants demonstrate that Gag encodes the functional target of cyclophilin A. J Virol (1996) 2.39
Cytoskeleton association and virion incorporation of the human immunodeficiency virus type 1 Vif protein. J Virol (1996) 2.30
The Vif protein of human and simian immunodeficiency viruses is packaged into virions and associates with viral core structures. J Virol (1995) 2.25
Spontaneous mutations in the human immunodeficiency virus type 1 gag gene that affect viral replication in the presence of cyclosporins. J Virol (1996) 2.07
Inhibition of human immunodeficiency virus type 1 replication by SDZ NIM 811, a nonimmunosuppressive cyclosporine analog. Antimicrob Agents Chemother (1994) 1.98
Absconding with the chaperone: essential cyclophilin-Gag interaction in HIV-1 virions. Cell (1996) 1.94
The effect of cytokines and pharmacologic agents on chronic HIV infection. AIDS Res Hum Retroviruses (1992) 1.90
The hydrophobic pocket of cyclophilin is the binding site for the human immunodeficiency virus type 1 Gag polyprotein. J Virol (1997) 1.84
Human immunodeficiency virus type 1 Vif does not influence expression or virion incorporation of gag-, pol-, and env-encoded proteins. J Virol (1996) 1.76
Inhibition of HIV-1 replication by cyclosporine A or related compounds correlates with the ability to disrupt the Gag-cyclophilin A interaction. Virology (1996) 1.74
Cyclophilin: distribution and variant properties in normal and neoplastic tissues. J Immunol (1986) 1.70
Characterization of human immunodeficiency virus type 1 Vif particle incorporation. J Virol (1996) 1.69
Transfer of the HIV-1 cyclophilin-binding site to simian immunodeficiency virus from Macaca mulatta can confer both cyclosporin sensitivity and cyclosporin dependence. Proc Natl Acad Sci U S A (1997) 1.68
Isomerase and chaperone activity of prolyl isomerase in the folding of carbonic anhydrase. Science (1992) 1.65
The effect of cyclosporine A on infection of susceptible cells by human immunodeficiency virus type 1. Blood (1988) 1.56
Inhibition of human immunodeficiency virus and growth of infected T cells by the immunosuppressive drugs cyclosporin A and FK 506. Proc Natl Acad Sci U S A (1992) 1.50
Proline isomerases function during heat shock. Proc Natl Acad Sci U S A (1993) 1.48
X-ray structure of a decameric cyclophilin-cyclosporin crystal complex. Nature (1993) 1.47
Solution structure of the cyclosporin A/cyclophilin complex by NMR. Nature (1993) 1.44
Inhibition of human immunodeficiency virus replication by nonimmunosuppressive analogs of cyclosporin A. Proc Natl Acad Sci U S A (1995) 1.42
Cyclophilin A complexed with a fragment of HIV-1 gag protein: insights into HIV-1 infectious activity. Structure (1997) 1.34
Active-site residues of cyclophilin A are crucial for its incorporation into human immunodeficiency virus type 1 virions. J Virol (1997) 1.25
Crystal structures of cyclophilin A complexed with cyclosporin A and N-methyl-4-[(E)-2-butenyl]-4,4-dimethylthreonine cyclosporin A. Structure (1994) 1.11
The HIV type 1 replication block in nonhuman primates is not explained by differences in cyclophilin A primary structure. AIDS Res Hum Retroviruses (1998) 0.96
Molecular insights into human immunodeficiency virus type 1 pathogenesis. Curr Opin Immunol (1992) 0.93
Specific incorporation of cyclophilin A into HIV-1 virions. Nature (1994) 7.13
The retinoblastoma protein and BRG1 form a complex and cooperate to induce cell cycle arrest. Cell (1994) 5.00
Specific antimononuclear phagocyte monoclonal antibodies. Application to the purification of dendritic cells and the tissue localization of macrophages. J Exp Med (1983) 4.68
Mapping of functionally important residues of a cysteine-histidine box in the human immunodeficiency virus type 1 nucleocapsid protein. J Virol (1993) 4.22
Cyclophilin A is required for an early step in the life cycle of human immunodeficiency virus type 1 before the initiation of reverse transcription. J Virol (1996) 4.15
Human immunodeficiency virus type 1 Vpr arrests the cell cycle in G2 by inhibiting the activation of p34cdc2-cyclin B. J Virol (1995) 3.69
Relative efficacy of human monocytes and dendritic cells as accessory cells for T cell replication. J Exp Med (1983) 3.20
Specific binding of human immunodeficiency virus type 1 gag polyprotein and nucleocapsid protein to viral RNAs detected by RNA mobility shift assays. J Virol (1993) 3.15
Cyclophilin A regulates HIV-1 infectivity, as demonstrated by gene targeting in human T cells. EMBO J (2001) 2.64
Linker insertion mutations in the human immunodeficiency virus type 1 gag gene: effects on virion particle assembly, release, and infectivity. J Virol (1995) 2.56
Specificity and sequence requirements for interactions between various retroviral Gag proteins. J Virol (1994) 2.50
Basic residues in human immunodeficiency virus type 1 nucleocapsid promote virion assembly via interaction with RNA. J Virol (2000) 2.46
Cyclosporine A-resistant human immunodeficiency virus type 1 mutants demonstrate that Gag encodes the functional target of cyclophilin A. J Virol (1996) 2.39
Translation elongation factor 1-alpha interacts specifically with the human immunodeficiency virus type 1 Gag polyprotein. J Virol (1999) 2.08
The hydrophobic pocket of cyclophilin is the binding site for the human immunodeficiency virus type 1 Gag polyprotein. J Virol (1997) 1.84
Inhibition of HIV-1 replication by cyclosporine A or related compounds correlates with the ability to disrupt the Gag-cyclophilin A interaction. Virology (1996) 1.74
Binding of the human immunodeficiency virus type 1 Gag polyprotein to cyclophilin A is mediated by the central region of capsid and requires Gag dimerization. J Virol (1996) 1.59
Human immunodeficiency virus type 1 virion density is not determined by nucleocapsid basic residues. J Virol (2000) 1.12
Isolation, characterization and targeted disruption of mouse ppia: cyclophilin A is not essential for mammalian cell viability. Genomics (2000) 1.10
Rescue of multiple viral functions by a second-site suppressor of a human immunodeficiency virus type 1 nucleocapsid mutation. J Virol (2000) 1.06
The HIV type 1 replication block in nonhuman primates is not explained by differences in cyclophilin A primary structure. AIDS Res Hum Retroviruses (1998) 0.96
HIV-1 Vpr: G2 cell cycle arrest, macrophages and nuclear transport. Prog Cell Cycle Res (1997) 0.90
HIV-1 and Ebola virus: the getaway driver nabbed. Nat Med (2001) 0.86
Cyclophilin binding to the human immunodeficiency virus type 1 Gag polyprotein is mimicked by an anti-cyclosporine antibody. J Virol (1995) 0.81
Cyclophilin and gag in HIV-1 replication and pathogenesis. Adv Exp Med Biol (1995) 0.80
Assignment of cyclophilin A (PPIA) to human chromosome band 7p13by in situ hybridization. Cytogenet Cell Genet (1996) 0.79
Context-dependent phenotype of a human immunodeficiency virus type 1 nucleocapsid mutation. J Virol (2001) 0.76
Physics of life. Nature (1993) 0.75